(S017) A Margin Reduction Study for the Treatment of Gastric Marginal Zone Lymphoma Utilizing a Magnetic Resonance Imaging–Guided Radiation Therapy (MRIgRT) System

News
Article
OncologyOncology Vol 30 No 4_Suppl_1
Volume 30
Issue 4_Suppl_1

Significant variability in clinical target volume localization of gastric marginal zone lymphoma occurs if daily RT is delivered based on alignment to bony anatomy. MRI-guided RT allows for significant reduction in planning target volumes expansions without compromising coverage.

Anupama Chundury, MD, Benjamin W. Fischer-Valuck, MD, Linnae Campbell, MS, Olga Green, PhD, Harold Li, PhD, Sasa Mutic, PhD, Maria Thomas, MD, PhD, Jiayi Huang, MD; Washington University School of Medicine

BACKGROUND: Radiation therapy (RT) is one of the major treatment modalities for localized gastric marginal zone lymphoma (GMZL). The purpose of this study was to correlate daily clinical target volumes (dCTVs) with planning target volumes (PTVs) in patients undergoing definitive RT for GMZL, utilizing a novel on-board magnetic resonance imaging– guided radiation therapy (MRIgRT) system. 

METHODS: Five patients with GMZL were treated with definitive RT using MRIgRT to a dose of 30 Gy in 20 fractions. Preceding RT, patients underwent treatment planning CT and MR simulations to delineate the CTV (entire stomach). Prior to delivery of each fraction, a daily pretreatment MRI (dMRI) was acquired for target localization. These dMRIs were manually registered to planning MRIs (pMRIs) based both on bony anatomy and then on planning CTVs (pCTVs). Retrospectively, pCTVs were recontoured and expanded by 5, 10, and 20 mm to generate new PTVs, which were then compared with recontoured pretreatment dCTVs to assess target overlap.

RESULTS: One hundred dMRIs were evaluated. Ninety-nine of 100 dCTVs had a smaller volume than the pCTVs; a 3-mm expansion of one pCTV was required to include the outlier dCTV. When dMRIs were registered to the pMRI based on bony anatomy, all dCTVs were outside a 5-mm expanded PTV, 92 were outside a 10-mm expanded PTV, and 50 were outside a 20-mm expanded PTV. No patients had all 20 dCTVs fully encompassed by a 20-mm expanded PTV. When dMRIs were registered to the pMRI based on CTVs, all dCTVs were fully encompassed within a 5-mm expanded PTV.

CONCLUSIONS: Significant variability in CTV localization of GMZL occurs if daily RT is delivered based on alignment to bony anatomy. MRIgRT, which provides improved localization of dCTVs, allows for significant reduction in PTV expansions without compromising coverage. A 5-mm PTV margin appears sufficient for MRIgRT.

Proceedings of the 98th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(S002) A 15-Year Review of Radiation Therapy for Keloids at Two Institutions
(S003) Single-Fraction Radiation Therapy for the Treatment of Multiple Myeloma Bony Metastases Provides Pain Control and Decreases Time to Chemotherapy
(S001) Prognostic Value of Pretreatment Serum Inflammatory Markers in Patients Receiving Radiation Therapy for Oropharyngeal Cancer
(S004) Trend in Second Malignancy Risk for Head and Neck Cancer With Increased Utilization of IMRT: Analysis of SEER Database
(S005) Comparison of Legal Needs of a Group of Patients With Cancer: Economic and Geographic Factors
(S006) Mission Improvement: Lessons From Initiating a Resident-Led Quality Improvement Project on Smoking Cessation at a County Hospital
(S007) Results of a Phase II Trial Using Cetuximab Plus Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma
(S008) The Effect of Simulation and Treatment Delays for Patients With Oropharyngeal Cancer Receiving Definitive Radiation Therapy in the Era of Risk Stratification Using Smoking and Human Papilloma Virus Status
(S009) Intensity-Modulated Radiation Therapy With Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on Three-Year Toxicity
(S011) Comparative Study Between Ileal Conduit and Indiana Pouch After Cystectomy for Patients With Carcinoma of Urinary Bladder
(S010) Computed Tomography–Assessed Measures of Bone Mineral Density and Muscle Mass as Predictors of Survival in Men With Prostate Cancer
(S012) Quantitative Imaging to Evaluate the Malignant Potential of Pancreatic Cysts
(S013) Spine Stereotactic Radiosurgery With Concurrent Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
(S014) The Impact of Radiation Therapy on Survival in Surgically Resected, High-Risk Patients With Ampullary Adenocarcinoma: A Population-Based Analysis
(S016) The Impact of Stereotactic Body Radiation Therapy on Overall Survival in Patients With Locally Advanced Pancreatic Cancer
Recent Videos
Preliminary phase 2 trial data show durvalumab plus lenalidomide was superior to durvalumab alone in refractory/advanced cutaneous T-cell lymphoma.
Developing odronextamab combinations following CAR T-cell therapy failure may help elicit responses in patients with diffuse large B-cell lymphoma.
Cytokine release syndrome was primarily low or intermediate in severity, with no grade 5 instances reported among those with diffuse large B-cell lymphoma.
Safety results from a phase 2 trial show that most toxicities with durvalumab treatment were manageable and low or intermediate in severity.
Investigators are currently evaluating mosunetuzumab in relapsed disease or comparing it with rituximab in treatment-naïve follicular lymphoma.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
Establishment of an AYA Lymphoma Consortium has facilitated a process to better understand and address gaps in knowledge for this patient group.
Adult and pediatric oncology collaboration in assessing nivolumab in advanced Hodgkin lymphoma facilitated the phase 3 SWOG S1826 findings.
Treatment paradigms differ between adult and pediatric oncologists when treating young adults with lymphoma.
Related Content